Kodiak Sciences Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi, everyone. My name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. It is with great pleasure that I would like to welcome Victor Perlroth, the CEO of Kodiak Sciences. Thanks so much for joining us today, Victor.
Thanks, Maury. Glad to be here.
Thanks. We are going to do fireside chat format.
Maybe for those who are new to the story, if you can give a brief intro to Kodiak.
Not sure. It is hard to put it all in a couple of words, but we call ourselves a pre-commercial retina-focused biotech company. We are developing medicines for the big diseases, by and large, in retina. We have had an exciting year so far. We had top-line data in March from the GLOW2 study, which is our drug, tarcocimab, or Zenkuda, in diabetic retinopathy. It was the second phase III, and it used our commercial or new formulation process, and it was a very strong, very exciting, very safe-looking medicine coming out of that second diabetic retinopathy study. Then we had that same drug in the DAYBREAK study. That had the readout in late September, actually alongside maybe its little brother, the KSI-501 bispecific conjugated medicine, both ABCs, we call them, antibody biopolymer conjugates, in treatment-naive wet AMD. That was also a very successful study. We were extremely pleased. Zenkuda, in particular, looked very strong against EYLEA in that treatment-naive wet AMD population.
Our objectives going into the study were to look for very strong immediacy of effect, as well as looking for long-interval durability. We were very pleased to see very powerful immediacy, tracking, if anything, better than EYLEA. Then we took the majority of the patients to six months dosing, with a very strong vision gain and efficacy through that kind of durability interval phase and through the endpoint. We used, I would say, a very honest study design in DAYBREAK, where the Zenkuda-treated patients. We used a sort of a very, very sensitive kind of algorithm. If any fluid fundamentally was present at the limit of sensitivity of these OCT machines, then the patient would be treated.
That meant that those durability kind of numbers of the majority being treated on six months really are what we call kind of real world. The physicians and the community can then expect to be able to see a very powerful immediacy in their patients, in the clinic, and also a fundamentally, I think, game-changing and disruptive level of durability. I think the readout really changes the game for all drug developers in retina, and forces everybody to think a little bit differently, because we have a biologic that fundamentally can deliver what everybody has sort of been trying to do, which is high efficacy/immediacy, which is what the current medicines, EYLEA HD, VABYSMO, deliver, what they give, and a really differentiated kind of durability.
I think, in advance of the DAYBREAK. Well, in advance of the GLOW2 study, I think, what we messaged is, I think, we thought maybe investor community was underappreciating the potential of the GLOW2 readout, because it was going to read through on the new formulation, and GLOW2 was sort of a repeat of the GLOW1 study. We did very well and showed a lot of strength in the GLOW2 readout. Then I think in advance of DAYBREAK, we were more measured. We didn't know. EYLEA is a very strong comparator in a mass study. What we did say is that our durability generally had over-delivered. Where we were weak was on that immediacy and some 10%-20% of the patients. We just didn't know how good we were going to be.
We thought going into the readout that we would be pretty good on the immediacy. We didn't know whether that meant slightly weaker than EYLEA, the same, or slightly better. We didn't know on the durability, because we had really used these unknown, very sensitive criteria. But we really blew through that, and that was very exciting and I guess a surprise. I think we also did well with the KSI-501 bispecific conjugate in wet AMD. Met the endpoint, and that sets the stage for that molecule to move in to the ALTO phase III study, which is enrolling in DME, and that's accelerating. But I think, having said that, historically, now we're in the face of the KSI-101 phase III readout, which is really a new indication area. It's going up against sham.
It's in a disease that we call MESI, which is inflammatory macular edema, or macular edema secondary to inflammation. Macular edema is what retina doctors treat today. It's just they're treating it for wet AMD, they're treating it for DME, they're treating it for RVO. We have a new agent, a very powerful, very strong agent going up against sham in the PEAK and PINNACLE pivotal program, and we're looking at the readout for PEAK 1 before Christmas. We're on track for that, obviously fully enrolled for PEAK 1. It's really a three-study pivotal program, and the first one is this first readout. As I've said publicly, I mean, I'm very excited and we're very excited for the readout.
This is a very powerful medicine in a very sick patient population, going up against sham, and we're hoping for a very powerful readout that could be really important for this very sick population, where there really is no therapy whatsoever. That's very good. Just to close out on an intro, we also set up a shelf and an ATM coming out of DAYBREAK. We did raise a little bit on the ATM over the past couple weeks, about $70 million, which is a nice bridge through the PEAK 1. From there, we would have an expectation to further capitalize the company. We're on track for the BLA for Zenkuda, tarcocimab, before the end of this year, in three indications of wet AMD, retinal vein occlusion and diabetic retinopathy. So that's very exciting. It's obviously a complicated multi-indication BLA with an antibody conjugate, so the teams are very busy on that.
We're quite busy on the PEAK 1, top-line data and the continuation of that program with PINNACLE and PEAK 2 and PINNACLE. We'd be focused on the BLA for that asset. Whether we can file on a single study, could potentially file in April. Alternatively, if we're going to wait for the PEAK 2 and PINNACLE's fully enrolled. PEAK 2 just has a few more patients to go, to be honest, with the 24-week endpoint. So we'd be looking at maybe May, June for top-line data for PEAK 2 and PINNACLE, and we could file with 48-week safety data on PEAK 1 together with primary endpoint data for PEAK 2 and PINNACLE, like mid-next year. So it's pretty exciting. The KSI-501, as I said, is in the ALTO-DME study, and that's accelerating.
We're quite excited about the potential for that bispecific conjugate with the free protein and the conjugate to really do something special in DME. In summary, we're a pretty interesting retina company, with three late-phase assets, BLAs targeted for this year, next year, and maybe 2028 for the third asset. Hopefully, we could be approved with Zenkuda by the end of 2027 and maybe be approved by 101, let's say, in early 2028. Those are major diseases. We have a lot of science underlining, underpinning what we do. We've learned a lot over the years, and we're trying to be more conservative in our phase III study designs. We've really turned some pretty differentiated data cards for Zenkuda, certainly in the big anti-VEGF market. I think KSI-101 can look really differentiated in this MESI market, which I do think is underappreciated in terms of its size.
I'll stop there. That was a great intro.
I think you covered everything.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
